https://www.selleckchem.com/pr....oducts/Mubritinib-TA
Posaconazole (POS) appears to have dose-proportional pharmacokinetics, however there is paucity of real-life data. We retrospectively evaluated 67 patients with hematological cancer who had POS dose increase from 300 mg/d to either 400 mg/d (n=52) or 300 mg twice daily (BID; n=15) and POS serum levels measured. Median POS levels were 840 ng/mL, 1625 ng/mL, and 2710 ng/mL on the 300mg/d, 400mg/d and 300mg BID doses respectively. Significant inter-patient variability in serum levels was noted.Objectives We investigated whether
Like
Comment
Share
